Abstract
Treatment for chronic viral hepatitis C has advanced dramatically to current standard of care all-oral direct-acting antiviral regimens with relatively short treatment duration and high efficacy. Patients with comorbid end-stage renal disease have constituted a "special patient population" with data and treatment options lagging behind that of the broader population of patients with chronic hepatitis C until recently. Herein we review the current evidence base for direct-acting antiviral therapy in this population. We provide a suggested algorithm for the evaluation of such patients for therapy. We highlight special considerations in regards to the choice of regimen, duration, and timing in regards to potential kidney transplantation.
Original language | English (US) |
---|---|
Pages (from-to) | 287-294 |
Number of pages | 8 |
Journal | Journal of Clinical Gastroenterology |
Volume | 52 |
Issue number | 4 |
DOIs | |
State | Published - Jan 1 2018 |
Keywords
- direct-acting antiviral therapy
- hepatitis C
- kidney transplant
- renal insufficiency
ASJC Scopus subject areas
- Gastroenterology